No Data
No Data
No Data
No Data
No Data
Actinium Says Phase 3 SIERRA Trial Results Of Iomab-B Shows Improving OS For AML Patients
RTTNewsApr 18 09:33 ET
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients With Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active re
PR NewswireApr 18 08:00 ET
Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. Amidst Groundbreaking Cancer Therapy Innovations
EvertiseApr 1 13:42 ET
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)
TipRanksApr 1 10:20 ET
Actinium's Phase 3 Trial Results Show Survival Benefit In Acute Myeloid Leukemia Patients; Stock Up
RTTNewsApr 1 10:04 ET
Actinium Pharmaceuticals Price Target Maintained With a $21.00/Share by Cantor Fitzgerald
Actinium Pharmaceuticals Price Target Maintained With a $21.00/Share by Cantor Fitzgerald
Dow JonesApr 1 08:32 ET
No Data
No Data